Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe

First FDA-approved treatment for COVID-19 includes use in adolescents

from the Food and Drug Administration’s Office of Pediatric Therapeutics and Center for Drug Evaluation and Research, Division of Pediatric and Maternal Health and Division of Antivirals
January 01, 2021
  • FDA Update

The Food and Drug Administration (FDA) has approved the antiviral Veklury (remdesivir) for treatment of COVID-19 requiring hospitalization in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms (kg).

Veklury is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor. It is administered by intravenous infusion as a single loading dose on day 1 followed by once-daily maintenance dosing beginning on day 2 for five to 10 days, depending on clinical severity and response.

The approval of Veklury was supported by the FDA’s analysis of data from three randomized, controlled trials in patients hospitalized with mild to severe COVID-19.

In one randomized, double-blind, placebo-controlled clinical trial, the FDA concluded that remdesivir treatment resulted in faster recovery (median 10 days) compared to placebo (median 15 days). The major safety issues identified were hepatotoxicity and hypersensitivity reactions, including infusion-related and anaphylactic reactions.

Pediatric approval was based on the following:

  • extrapolation of efficacy data from adults because COVID-19 and the response to remdesivir therapy in adolescents is likely to be similar to adults;
  • pharmacokinetic modeling and simulation demonstrating the dosing regimen in adults is expected to result in comparable exposures in pediatric patients 12 years and older weighing at least 40 kg;
  • the safety profile in adults weighing 40-50 kg was comparable to adults weighing more than 50 kg; and
  • data from 39 pediatric patients 12 years and older weighing at least 40 kg who received remdesivir in a compassionate use program.

An ongoing trial is evaluating the safety, tolerability, pharmacokinetics and treatment response of remdesivir in pediatric patients with COVID-19, including term and preterm neonates (https://clinicaltrials.gov/ct2/show/NCT04431453).

To ensure continued access to the pediatric population previously covered under the emergency use authorization (EUA), the FDA revised the EUA for Veklury to authorize treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized patients younger than 12 years weighing at least 3.5 kg.

Resources
  • Veklury prescribing information
  • Information on FDA’s approval of Veklury
  • Additional information on FDA’s approval of Veklury
  • FDA’s summary review of Veklury
  • Coronavirus Treatment Acceleration Program
  • Additional FDA Update columns
Copyright © 2021 American Academy of Pediatrics

Advertising Disclaimer »

Download PDF
Email News Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First FDA-approved treatment for COVID-19 includes use in adolescents
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First FDA-approved treatment for COVID-19 includes use in adolescents
from the Food and Drug Administration’s Office of Pediatric Therapeutics and Center for Drug Evaluation and Research, Division of Pediatric and Maternal Health and Division of Antivirals
January 01, 2021
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Digital Edition Current Issue
  • Latest Daily News
  • Archives
  • Collections
  • Columns
  • Advertising
  • Subscribe to AAP News Magazine
  • Terms of Use
  • Privacy Statement
  • FAQ
  • Contact Us
  • 2021 AAP Journals Catalog
  • Pediatrics
  • Pediatrics in Review
  • Hospital Pediatrics
  • NeoReviews
  • AAP Grand Rounds
  • AAP Career Center
  • shopAAP
  • AAP.org
  • AAP News
  • Visit AAP News on Facebook
  • Follow AAP News on Twitter
American Academy of Pediatrics

© 2021 American Academy of Pediatrics